Suppr超能文献

COVID-19 大流行时期的皮肤病学实践。

Dermatology practice in the times of the COVID-19 pandemic.

机构信息

Department of Dermatology, AFMC and Command Hospital, Pune, Maharashtra, India.

出版信息

Indian J Dermatol Venereol Leprol. 2021 Sep-Oct;87(5):603-610. doi: 10.25259/IJDVL_364_20.

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is implicated in the ongoing pandemic across the globe since December 2019. It was first notified by China from Wuhan on 31 December 2020 and transmission to healthcare workers was first reported on 20 January 2020. Human-to-human transmission is mainly by droplet infection. At present no effective vaccine is available. Our speciality needs to collectively address the urgent issue of risk of transmission in dermatology practice. A case series of Coronavirus Disease 2019 (COVID-19) from Wuhan described that 41.3% of their patients may have acquired the infection from the hospital. Of all the infected health care workers, 77.5% worked in general wards and departments. These data highlight the significant risk of nosocomial transmission of COVID-19 and also the higher risk in general wards and departments compared to the emergency room or intensive care unit. Dermatology patients are generally seen in clinics and in outpatient departments in hospitals. Patients wait together in the waiting area, intermingle and then are seen by the physician in their chamber. This can cause transmission of the pathogen among patients and from patient to physician. Social distancing, hand hygiene and the use of personal protective equipment are important for preventing the spread of infection and dermatology practices also have to incorporate these aspects. Telemedicine is becoming an important tool for the management of dermatology patients in these times. At-risk patients in dermatology also need to be given priority care. Protocols for the use of immunosuppressants and biologics in dermatology during the pandemic are being developed.

摘要

严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)自 2019 年 12 月以来在全球范围内引发了持续的大流行。它于 2020 年 12 月 31 日首次由中国武汉通报,并于 2020 年 1 月 20 日首次报告传播给医护人员。人与人之间的传播主要是通过飞沫感染。目前尚无有效的疫苗。我们的专业需要共同解决皮肤科实践中传播风险的紧迫问题。来自武汉的 2019 年冠状病毒病(COVID-19)的病例系列描述说,他们的 41.3%的患者可能是在医院感染的。在所有受感染的医护人员中,77.5%在普通病房和科室工作。这些数据突出了 COVID-19 医院内传播的巨大风险,并且普通病房和科室的风险高于急诊室或重症监护病房。皮肤科患者通常在诊所和医院的门诊部就诊。患者在等候区一起等待,相互混合,然后在诊室由医生就诊。这会导致病原体在患者之间以及从患者传播给医生。保持社交距离,手部卫生和使用个人防护设备对于预防感染传播非常重要,皮肤科实践也必须将这些方面纳入其中。远程医疗在当前已成为管理皮肤科患者的重要工具。在皮肤科中,高危患者也需要优先护理。正在制定皮肤科在大流行期间使用免疫抑制剂和生物制剂的方案。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验